ReviewFrontiers in oncology2026
Post-oncologic skin health: cutaneous recovery and rehabilitation after cancer treatments.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Advances in oncology have markedly improved cancer survival, however, chronic cutaneous sequelae induced by chemotherapy, radiotherapy, targeted therapies, and immunotherapies remain common and may persist long after treatment completion. These long-term skin changes, ranging from xerosis and pruritus to pigmentary alterations, fibrosis, and immune-mediated dermatoses, can substantially impair quality of life and functional recovery. Objective: To define the evolving role of dermatology in post-oncologic skin health and to critically synthesize mechanistic and clinical evidence supporting long-term dermatologic rehabilitation strategies. Methods: A structured search of PubMed and MEDLINE (2010-2025) identified clinical and mechanistic studies, consensus guidelines, systematic reviews, and cohort data relevant to post-treatment cutaneous sequelae. Eligible publications included human studies addressing chronic skin changes after cancer therapy or evaluating therapeutic approaches applicable to survivorship dermatology. The search yielded 612 records, of which 148 full-text articles were reviewed and 54 met the inclusion criteria for synthesis. Results: Post-oncologic skin care extends beyond symptomatic management to encompass restoration of epidermal barrier function, mitigation of chronic inflammation, support of the cutaneous microbiome, and improvement of psychosocial well-being. Mechanistic studies highlight persistent structural, immunologic, molecular, and microbial alterations that underline delayed skin recovery. Within this context, photobiomodulation and selective energy-based modalities may support long-term cutaneous resilience, however robust clinical evidence of their benefit is lacking. Conclusion: Dermatologists play a central role in survivorship care by transitioning cutaneous management from symptomatic treatment toward preventive, restorative, and rehabilitative strategies that improve long-term quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.